Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers

AIDS

Volumn 15, Issue 10, 2001, Pages 1239-1249

  Pialoux, G ^a   Gahery Segard H ^a   Sermet, S ^a   Poncelet, H ^a   Fournier, S ^a   Gerard L ^a   Tartar, A ^a   Gras Masse, H ^a   Levy, J P ^a   Guillet, J G ^a  

^a HÔPITAL ROTHSCHILD   (France)

Author keywords

Cytotoxic lymphocyte; HIV 1; Lipopeptides; Lymphoproliferation; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LIPOPEPTIDE;

ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE; WESTERN BLOTTING;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, NEF; HIV ANTIBODIES; HIV SERONEGATIVITY; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0035816391     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107060-00005     Document Type: Article

References (30)

1. Candidate AIDS vaccines
2. Safety profile of phase I and II preventive HIV1 envelop vaccination: Experience of the NIAID AIDS vaccine evaluation group
3. Immune responses elicited by recombinant vaccinia-HIV envelop and HIV envelop potein: Analysis of the durability of responses and effect of repeated boosting
4. The prime-boost concept applied to HIV preventive vaccines
5. A prime-boost approach to HIV preventive vaccine using a recombinant canary pox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
6. Immune responses to HIV1 induced by canarypox expressing HIV1-MN gp120, HIV1-SF2 recombinant gp120 or both vaccines in seronegative adults
7. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines
8. 1 and boosted with a recombinant gp 160
9. Lipopeptide immunisation without adjuvant induces potent and long-lasting B, Th and CTL responses against a malaria liver stage antigen in mice and chimpanzee(s)
10. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG or NEF specific cytofoxic T lymphocytes by lipopeptides
11. Analysis of physical interactions between peptides and HLA molecules and application to the detection of human immunodeficiency virus 1 antigenic peptides
12. Physical association betxeen MHC class T molecules and immunogenic peptides
13. An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individual in association with different HLA-B molecules
14. + T cells in the central region of the HIV-1 NEF protein
15. Identification of multi-restricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein
16. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL
17. In vivo priming of virus-specific cytotoxic T lymphocytes and synthetic lipopeptide vaccine
18. Comparison of the immune response clicited by a free peptide and a lipopeptide construct
19. Weak anti-HIV CD8+ T-cell effector activity in HIV primary infection
20. Broad intense anti-human immunodeficiency virus (HIV) Ex-vivo CD8+ responses in HIV type-1 -infected patients: Comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy
21. A simple assay for detection of peptides promoting the assembly of HLA class I molecules
22. Impaired CTL recognition due to genetic variations in the main immunogenic region of the HIV-1 Nef protein
23. Multiepitopic B and T cell responses induced in humans by an HIV-1 lipopeptide vaccine
24. Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate
25. Neutralization of primary HIV1 isolates: A study of parameters implicated in neutralization in vitro
26. Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients
27. Clade B-based HIV1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
28. Persisting HIV1 gp160-specific human T lymphocytes responses including CD8+ cytotoxic activity after receipt of envelop vaccines
29. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
30. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmme gp 160 vaccines